Articles citing this paper
A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program
Shalini Kulasingam A J , Luke Connelly B , Elizabeth Conway C , Jane S. Hocking D , Evan Myers E , David G. Regan F , David Roder G , Jayne Ross H and Gerard Wain I
+ Author Affiliations
- Author Affiliations
A Duke University, Center for Clinical Health Policy Research, Durham, NC 27710, USA.
B The University of Queensland, Mayne Medical School, Herston, Qld 4006, Australia.
C CSL Limited, Parkville, Vic. 3052, Australia.
D The University of Melbourne, Parkville, Vic. 3010, Australia.
E Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA.
F National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, Darlinghurst, NSW 2010, Australia.
G Group Executive, Research and Information Science, The Cancer Council South Australia, Unley, SA 5061, Australia.
H Jayne Ross & Associates, Cheltenham, NSW 2118, Australia.
I Department of Gynaecological Oncology, Westmead Hospital, Westmead, NSW 2145, Australia.
J Corresponding author. Email: kulas002@mc.duke.edu
Sexual Health 4(3) 165-175 https://doi.org/10.1071/SH07043
Submitted: 19 June 2007 Accepted: 22 June 2007 Published: 23 August 2007
78 articles found in Crossref database.
Structural differences among cost–effectiveness models of human papillomavirus vaccines
Insinga Ralph P,
Dasbach Erik J, Elbasha Elamin H
Expert Review of Vaccines. 2008 7(7). p.895
Should human papillomavirus vaccination target women over age 26, heterosexual men and men who have sex with men? A targeted literature review of cost-effectiveness
Soe Nyi Nyi,
Ong Jason J.,
Ma Xiaomeng,
Fairley Christopher K,
Latt Phyu Mon,
Jing Jun,
Cheng Feng, Zhang Lei
Human Vaccines & Immunotherapeutics. 2018 14(12). p.3010
Epidemiological and Economic Impact of Human Papillomavirus Vaccines
Jeurissen Sarah, Makar Amin
International Journal of Gynecological Cancer. 2009 19(4). p.761
Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries
Simonella Leonardo, Canfell Karen
Vaccine. 2015 33(1). p.34
The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa
Sinanovic Edina,
Moodley Jennifer,
Barone Mark A.,
Mall Sumaya,
Cleary Susan, Harries Jane
Vaccine. 2009 27(44). p.6196
The cost-effectiveness of male HPV vaccination in the United States
Chesson Harrell W.,
Ekwueme Donatus U.,
Saraiya Mona,
Dunne Eileen F., Markowitz Lauri E.
Vaccine. 2011 29(46). p.8443
Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
Vokó Zoltán,
Nagyjánosi László, Kaló Zoltán
BMC Public Health. 2012 12(1).
Human Papillomavirus and Oropharyngeal Cancer Among Indigenous Australians: Protocol for a Prevalence Study of Oral-Related Human Papillomavirus and Cost-Effectiveness of Prevention
Jamieson Lisa,
Garvey Gail,
Hedges Joanne,
Mitchell Amanda,
Dunbar Terry,
Leane Cathy,
Hill Isaac,
Warren Kate,
Brown Alex,
Ju Xiangqun,
Roder David,
Logan Richard,
Johnson Newell,
Smith Megan,
Antonsson Annika, Canfell Karen
JMIR Research Protocols. 2018 7(6). p.e10503
Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage
Võrno Triin,
Lutsar Katrin,
Uusküla Anneli,
Padrik Lee,
Raud Terje,
Reile Rainer,
Nahkur Oliver, Kiivet Raul-Allan
Vaccine. 2017 35(46). p.6329
Parental acceptability of HPV vaccination for boys and girls aged 9–13 years in China – A population-based study
Wang Zixin,
Wang Jingjing,
Fang Yuan,
Gross Danielle L.,
Wong Martin C.S.,
Wong Eliza L.Y., Lau Joseph T.F.
Vaccine. 2018 36(19). p.2657
Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses
Diaz Mireia,
de Sanjosé Silvia,
Bosch F. Xavier, Bruni Laia
Reports of Practical Oncology & Radiotherapy. 2018 23(6). p.484
Human papillomavirus vaccination in low-resource countries: lack of evidence to support vaccinating sexually active women
Tsu V,
Murray M, Franceschi S
British Journal of Cancer. 2012 107(9). p.1445
Economic evaluations of massive HPV vaccination: Within-study and between study variations in incremental cost per QALY gained
Puig-Junoy Jaume, Lopez-Valcarcel Beatriz G.
Preventive Medicine. 2009 48(5). p.444
A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females
Anonychuk Andrea M,
Bauch Chris T,
Merid Maraki Fikre,
Van Kriekinge Georges, Demarteau Nadia
BMC Public Health. 2009 9(1).
For debate: that Australia should continue using the quadrivalent vaccine
Wain Gerard
Sexual Health. 2010 7(3). p.235
Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study
Georgousakis Melina,
Jayasinghe Sanjay,
Brotherton Julia,
Gilroy Nicole,
Chiu Clayton, Macartney Kristine
The Lancet Infectious Diseases. 2012 12(8). p.627
Assessing the Long-Term Role of Vaccination against HPV after Loop Electrosurgical Excision Procedure (LEEP): A Propensity-Score Matched Comparison
Bogani Giorgio,
Raspagliesi Francesco,
Sopracordevole Francesco,
Ciavattini Andrea,
Ghelardi Alessandro,
Simoncini Tommaso,
Petrillo Marco,
Plotti Francesco,
Lopez Salvatore,
Casarin Jvan,
Serati Maurizio,
Pinelli Ciro,
Valenti Gaetano,
Bergamini Alice,
Giannella Barbara,
Dell’Acqua Andrea,
Monti Ermelinda,
Vercellini Paolo,
D’ippolito Giovanni,
Aguzzoli Lorenzo,
Mandato Vincenzo D,
Carunchio Paola,
Carlifante Gabriele,
Giannella Luca,
Scaffa Cono,
Falcone Francesca,
Ferla Stefano,
Borghi Chiara,
Ditto Antonino,
Malzoni Mario,
Giannini Andrea,
Salerno Maria Giovanna,
Liberale Viola,
Contino Biagio,
Donfrancesco Cristina,
Desiato Michele,
Perrone Anna Myriam,
Dondi Giulia,
De Iaco Pierandrea,
Leone Roberti Maggiore Umberto,
Signorelli Mauro,
Chiappa Valentina,
Ferrero Simone,
Sarpietro Giuseppe,
Matarazzo Maria G,
Cianci Antonio,
Bocio Sara,
Ruisi Simona,
Guerrisi Rocco,
Brusadelli Claudia,
Mosca Lavinia,
Tinelli Raffaele,
De Vincenzo Rosa,
Zannoni Gian Franco,
Ferrandina Gabriella,
Dessole Salvatore,
Angioli Roberto,
Greggi Stefano,
Spinillo Arsenio,
Ghezzi Fabio,
Colacurci Nicola,
Fischetti Margherita,
Carlea Annunziata,
Zullo Fulvio,
Muzii Ludovico,
Scambia Giovanni,
Benedetti Panici Pierluigi, Di Donato Violante
Vaccines. 2020 8(4). p.717
Towards the eradication of HPV infection through universal specific vaccination
Crosignani Piergiorgio,
De Stefani Antonella,
Fara Gaetano Maria,
Isidori Andrea M,
Lenzi Andrea,
Liverani Carlo Antonio,
Lombardi Alberto,
Mennini Francesco Saverio,
Palu’ Giorgio,
Pecorelli Sergio,
Peracino Andrea P,
Signorelli Carlo, Zuccotti Gian Vincenzo
BMC Public Health. 2013 13(1).
Human papillomavirus vaccine coverage among female Australian adolescents: success of the school‐based approach
Brotherton Julia M L,
Murray Sharron L,
Hall Madeline A,
Andrewartha Lynne K,
Banks Carolyn A,
Meijer Dennis,
Pitcher Helen C,
Scully Megan M, Molchanoff Luda
Medical Journal of Australia. 2013 199(9). p.614
Vacuna contra el virus del papiloma humano: razones para el optimismo y razones para la prudencia
Ángel Martínez-González Miguel,
Carlos Silvia, de Irala Jokin
Medicina Clínica. 2008 131(7). p.256
“I want the one for older women” — extending the human papillomavirus vaccine population base
Wain Gerard V
Medical Journal of Australia. 2008 188(9). p.501
Cost-effectiveness of a bivalent human papillomavirus vaccination program in Japan
Connelly Luke B., Le Ha N. D.
Sexual Health. 2015 12(6). p.520
Human papillomavirus vaccines: an outsider’s point of view
Trollfors Birger
Expert Review of Vaccines. 2008 7(8). p.1131
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer
Saslow Debbie,
Solomon Diane,
Lawson Herschel W.,
Killackey Maureen,
Kulasingam Shalini L.,
Cain Joanna,
Garcia Francisco A. R.,
Moriarty Ann T.,
Waxman Alan G.,
Wilbur David C.,
Wentzensen Nicolas,
Downs Levi S.,
Spitzer Mark,
Moscicki Anna‐Barbara,
Franco Eduardo L.,
Stoler Mark H.,
Schiffman Mark,
Castle Philip E., Myers Evan R.
CA: A Cancer Journal for Clinicians. 2012 62(3). p.147
Aggregation and Competitive Exclusion: Explaining the Coexistence of Human Papillomavirus Types and the Effectiveness of Limited Vaccine Conferred Cross-Immunity
Waters E. K.
Acta Biotheoretica. 2012 60(4). p.333
Assessment of the cost–effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model
Dasbach Erik J,
Largeron Nathalie, Elbasha Elamin H
Expert Review of Pharmacoeconomics & Outcomes Research. 2008 8(5). p.491
Cost‐effectiveness of human papilloma virus vaccination in Iceland
ODDSSON KRISTJAN,
JOHANNSSON JAKOB,
ASGEIRSDOTTIR TINNA LAUFEY, GUDNASON THOROLFUR
Acta Obstetricia et Gynecologica Scandinavica. 2009 88(12). p.1411
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer
Saslow Debbie,
Solomon Diane,
Lawson Herschel W.,
Killackey Maureen,
Kulasingam Shalini L.,
Cain Joanna M.,
Garcia Francisco A. R.,
Moriarty Ann T.,
Waxman Alan G.,
Wilbur David C.,
Wentzensen Nicolas,
Downs Levi S.,
Spitzer Mark,
Moscicki Anna-Barbara,
Franco Eduardo L.,
Stoler Mark H.,
Schiffman Mark,
Castle Philip E., Myers Evan R.
Journal of Lower Genital Tract Disease. 2012 16(3). p.175
Vaccination against HPV virus: a systematic review of economic evaluation studies for developed countries
Kostaras Dimitris,
Karampli Eleftheria, Athanasakis Kostas
Expert Review of Pharmacoeconomics & Outcomes Research. 2019 19(2). p.147
Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan
Liu Pang-Hsiang,
Hu Fu-Chang,
Lee Ping-Ing,
Chow Song-Nan,
Huang Chao-Wan, Wang Jung-Der
BMC Health Services Research. 2010 10(1).
Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006–January 2008
Koulova Anna,
Tsui Jennifer,
Irwin Kathleen,
Van Damme Pierre,
Biellik Robin, Aguado Maria Teresa
Vaccine. 2008 26(51). p.6529
What needs to change to increase chlamydia screening in general practice in Australia? The views of general practitioners
Hocking Jane S,
Parker Rhian M,
Pavlin Natasha,
Fairley Christopher K, Gunn Jane M
BMC Public Health. 2008 8(1).
Universal human papillomavirus vaccination of Australian boys — neither cost‐effective nor equitable
Massey Peter D, Durrheim David N
Medical Journal of Australia. 2012 196(7). p.446
Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review
Herdman Michael,
Cole Amanda,
Hoyle Christopher K.,
Coles Victoria,
Carroll Stuart, Devlin Nancy
Value in Health. 2016 19(2). p.255
Knowledge, Attitudes, and Perceptions of the Arabic-Speaking Community in Sydney, Australia, toward the Human Papillomavirus (HPV) Vaccination Program: A Qualitative Study
Netfa Faeza,
King Catherine,
Davies Cristyn,
Rashid Harunor,
Tashani Mohamed,
Booy Robert, Skinner S. Rachel
Vaccines. 2021 9(9). p.940
Cost-effectiveness of human papillomavirus vaccination in Belgium: Do not forget about cervical cancer screening
Thiry Nancy,
De Laet Chris,
Hulstaert Frank,
Neyt Mattias,
Huybrechts Michel, Cleemput Irina
International Journal of Technology Assessment in Health Care. 2009 25(02). p.161
Using Facebook to Recruit Young Australian Men Into a Cross-Sectional Human Papillomavirus Study
Das Roopa,
Machalek Dorothy A,
Molesworth Edmund G, Garland Suzanne M
Journal of Medical Internet Research. 2017 19(11). p.e389
National survey of general practitioners' experience of delivering the National Human Papillomavirus Vaccination Program
Brotherton Julia M. L.,
Leask Julie,
Jackson Cath,
McCaffery Kirsten, Trevena Lyndal J.
Sexual Health. 2010 7(3). p.291
Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand
Blakely Tony,
Kvizhinadze Giorgi,
Karvonen Tanja,
Pearson Amber L.,
Smith Megan, Wilson Nick
Vaccine. 2014 32(22). p.2645
Economic evaluation of skin cancer prevention in Australia
Shih Sophy Ting-Fang,
Carter Rob,
Sinclair Craig,
Mihalopoulos Cathrine, Vos Theo
Preventive Medicine. 2009 49(5). p.449
Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine
Marra Fawziah,
Cloutier Karine,
Oteng Bridgette,
Marra Carlo, Ogilvie Gina
PharmacoEconomics. 2009 27(2). p.127
Human papillomavirus vaccination and Pap testing profile in Manitoba, Canada
Kliewer Erich V.,
Mahmud Salaheddin M.,
Demers Alain A., Lambert Pascal
Vaccine. 2013 32(1). p.33
A revision of sexual mixing matrices in models of sexually transmitted infection
Walker Robert,
Nickson Carolyn,
Lew Jie‐Bin,
Smith Megan, Canfell Karen
Statistics in Medicine. 2012 31(27). p.3419
The economic burden of human papillomavirus-related precancers and cancers in Sweden
Östensson Ellinor,
Silfverschiöld Maria,
Greiff Lennart,
Asciutto Christine,
Wennerberg Johan,
Lydryp Marie-Louise,
Håkansson Ulf,
Sparén Pär,
Borgfeldt Christer, McLaughlin-Drubin Margaret
PLOS ONE. 2017 12(6). p.e0179520
Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26?
Skinner S Rachel,
Garland Suzanne M,
Stanley Margaret A,
Pitts Marian, Quinn Michael A
Medical Journal of Australia. 2008 188(4). p.238
The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia
Smith Megan A.,
Lew Jie-Bin,
Walker Robert J.,
Brotherton Julia M.L.,
Nickson Carolyn, Canfell Karen
Vaccine. 2011 29(48). p.9112
Cost-effectiveness of a cervical screening program with human papillomavirus vaccine
Sopina Elizaveta, Ashton Toni
International Journal of Technology Assessment in Health Care. 2011 27(4). p.290
Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model
Usher Cara,
Tilson Lesley,
Olsen Jens,
Jepsen Martin,
Walsh Cathal, Barry Michael
Vaccine. 2008 26(44). p.5654
Herd immunity: recent uses in vaccine assessment
Gonçalves Guilherme
Expert Review of Vaccines. 2008 7(10). p.1493
A cost–utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme
Dee Anne, Howell Fenton
European Journal of Public Health. 2010 20(2). p.213
Aspects of Prophylactic Vaccination against Cervical Cancer and Other Human Papillomavirus-Related Cancers in Developing Countries
Natunen Kari,
Lehtinen Johannes,
Namujju Proscovia,
Sellors John, Lehtinen Matti
Infectious Diseases in Obstetrics and Gynecology. 2011 2011 p.1
Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies
Ben Hadj Yahia Mohamed-Béchir,
Jouin-Bortolotti Anaïs, Dervaux Benoît
Clinical Drug Investigation. 2015 35(8). p.471
A critical review of cost-effectiveness analyses of vaccinating males against human papillomavirus
Jiang Yiling,
Gauthier Aline,
Postma Maarten J,
Ribassin-Majed Laureen,
Largeron Nathalie, Bresse Xavier
Human Vaccines & Immunotherapeutics. 2013 9(11). p.2285
Prevention of HPV-Related Cancers in Norway: Cost-Effectiveness of Expanding the HPV Vaccination Program to Include Pre-Adolescent Boys
Burger Emily A.,
Sy Stephen,
Nygård Mari,
Kristiansen Ivar S.,
Kim Jane J., Liu Xuefeng
PLoS ONE. 2014 9(3). p.e89974
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer
Saslow Debbie,
Solomon Diane,
Lawson Herschel W.,
Killackey Maureen,
Kulasingam Shalini L.,
Cain Joanna,
Garcia Francisco A. R.,
Moriarty Ann T.,
Waxman Alan G.,
Wilbur David C.,
Wentzensen Nicolas,
Downs Levi S.,
Spitzer Mark,
Moscicki Anna-Barbara,
Franco Eduardo L.,
Stoler Mark H.,
Schiffman Mark,
Castle Philip E., Myers Evan R.
American Journal of Clinical Pathology. 2012 137(4). p.516
Acceptance of human papillomavirus vaccination among first year female university students in Hong Kong
Wong William C. W.,
Fong Ben, Chan Paul K. S.
Sexual Health. 2009 6(4). p.264
Modeling Cervical Cancer Prevention in Developed Countries
Kim Jane J.,
Brisson Marc,
Edmunds W. John, Goldie Sue J.
Vaccine. 2008 26 p.K76
Human Papillomavirus Infections Among Couples in New Sexual Relationships
Burchell Ann N.,
Tellier Pierre-Paul,
Hanley James,
Coutlée François, Franco Eduardo L.
Epidemiology. 2010 21(1). p.31
A brief history of economic evaluation for human papillomavirus vaccination policy
Beutels Philippe, Jit Mark
Sexual Health. 2010 7(3). p.352
Adaptive Markov chain Monte Carlo forward projection for statistical analysis in epidemic modelling of human papillomavirus
Korostil Igor A.,
Peters Gareth W.,
Cornebise Julien, Regan David G.
Statistics in Medicine. 2013 32(11). p.1917
The incidence of genital warts in Australian women prior to the national vaccination program
Brotherton Julia M. L.,
Heywood Anita, Heley Stella
Sexual Health. 2009 6(3). p.178
Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs
Isidean Sandra D,
Tota Joseph E,
Gagnon Julien A, Franco Eduardo L
Expert Review of Vaccines. 2015 14(1). p.119
The attitudes of Australian gynaecologists to HPV vaccination: An ASCCP survey
TAN Jeffrey,
FARRELL Louise, ALLEN David G.
Australian and New Zealand Journal of Obstetrics and Gynaecology. 2010 50(5). p.472
Sexual risk assessment is not helpful for recommendations on human papillomavirus vaccination
Skinner Rachel, Brotherton Julia
Therapy. 2008 5(3). p.283
A study of physicians’ experiences with recommending HPV vaccines to adolescent boys
Wong Li Ping,
Edib Zobaida,
Alias Haridah,
Mohamad Shakir Sharina M.,
Raja Muhammad Yusoff Raja N. A.,
Sam I-Ching, Zimet Gregory D.
Journal of Obstetrics and Gynaecology. 2017 37(7). p.937
Cost–effectiveness of catch-up programs in human papillomavirus vaccination
de Peuter Maria A,
Littlewood Kavi J,
Annemans Lieven,
Largeron Nathalie, Quilici Sibilia
Expert Review of Vaccines. 2010 9(10). p.1187
Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine
Zhang Zhigang,
Zhang Jun,
Xia Ningshao, Zhao Qinjian
Human Vaccines & Immunotherapeutics. 2017 13(10). p.2280
Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia
Regan David G.,
Philp David J.,
Hocking Jane S., Law Matthew G.
Sexual Health. 2007 4(3). p.147
HPV vaccine: Not immune to controversy
Hammoud Maya
International Journal of Gynecology & Obstetrics. 2008 101(2). p.123
Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend
Gervais Frédéric,
Dunton Kyle,
Jiang Yiling, Largeron Nathalie
BMC Public Health. 2017 17(1).
Models of cervical screening in the era of human papillomavirus vaccination
Canfell Karen
Sexual Health. 2010 7(3). p.359
The Cost Effectiveness of Human Papillomavirus Vaccines
Seto Katherine,
Marra Fawziah,
Raymakers Adam, Marra Carlo A.
Drugs. 2012 72(5). p.715
The Health and Economic Impact of Cervical Cancer Screening and Human Papillomavirus Vaccination in Kidney Transplant Recipients
Wong Germaine,
Howard Kirsten,
Webster Angela,
Chapman Jeremy R., Craig Jonathan C.
Transplantation. 2009 87(7). p.1078
Eficiencia de los fármacos de origen biotecnológico en el marco terapéutico actual, según los estudios farmacoeconómicos disponibles
Figueredo Juan Luís Saucedo,
Bautista Susana Clemente,
Barrenechea Luís Mendarte, Ronsano José Bruno Montoro
PharmacoEconomics Spanish Research Articles. 2008 5(4). p.119
Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination
Östensson Ellinor,
Fröberg Maria,
Leval Amy,
Hellström Ann-Cathrin,
Bäcklund Magnus,
Zethraeus Niklas,
Andersson Sonia, Consolaro Marcia Edilaine Lopes
PLOS ONE. 2015 10(9). p.e0139062
Surveillance of Vaccination Coverage among Adult Populations — United States, 2015
Williams Walter W.,
Lu Peng-Jun,
O’Halloran Alissa,
Kim David K.,
Grohskopf Lisa A.,
Pilishvili Tamara,
Skoff Tami H.,
Nelson Noele P.,
Harpaz Rafael,
Markowitz Lauri E.,
Rodriguez-Lainz Alfonso, Fiebelkorn Amy Parker
MMWR. Surveillance Summaries. 2017 66(11). p.1
Analysis of the Economic and Socio-Demographic Burden of HPV-Associated Diseases and the Cost-Effectiveness of HPV Vaccination in Russia
Baranov Alexander A.,
Plakida Alexander V.,
Namazova-Baranova Leyla S.,
Semenov Mikhail A.,
Ilyushina Olga V.,
Guretskiy Yevgeniy V.,
Fedoseenko Marina V., Rudakova Alla V.
Pediatric pharmacology. 2019 16(2). p.101
Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis
Van de Velde Nicolas,
Brisson Marc, Boily Marie-Claude
Vaccine. 2010 28(33). p.5473
